Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

LVAD Patients' infection risks under the microscope

NCT ID NCT07255716

Knowledge-focused Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 120 adults getting a left ventricular assist device (LVAD) to see how often infections happen and how their immune system changes after surgery. The goal is to find what makes some patients more likely to get infections. This research does not test a new treatment but aims to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients receiving LVAD implantation who meet the inclusion criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (i) age \>18 years, (ii) indication for LVAD implantation, (iii)informed consent. Exclusion Criteria: (i) active preoperative infection (ii) other circulatory support devices were used preoperatively

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Driveline heart-assisted device related infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

advanced heart failure Infections infectious disease infectious disease with sepsis pneumonia prosthesis-related infectious disease Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Driveline heart-assisted device related infection Infection Pneumonia Sepsis

Contacts and locations

Locations

  • Fuwai Hospital

    Beijing, Xicheng, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.